(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 March 2011 (24.03.2011)

PCT

(10) International Publication Number
WO 2011/034907 A2

(51) International Patent Classification:
A61K 31/519 (2006.01) *C12N 9/12* (2006.01)

(21) International Application Number:
PCT/US2010/048916

(22) International Filing Date:
15 September 2010 (15.09.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/242,988 16 September 2009 (16.09.2009) US

(71) Applicant *(for all designated States except US)*: **AVILA THERAPEUTICS, INC.** [US/US]; 100 Beaver Street, Waltham, Massachusetts 02453 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SINGH, Juswinder** [GB/US]; 94 Heritage Avenue, Ashland, Massachusetts 01721 (US). **PETTER, Russell Colyn** [US/US]; 22 Robinwood Lane, Stow, Massachusetts 01775 (US). **NIU, Deqiang** [US/US]; 30 Grapevine Avenue, Lexington, Massachusetts 02421 (US). **QIAO, Lixin** [US/US]; 101 Merrimack Meadows Lane, Tewksbury, Massachusetts 01876 (US). **KLUGE, Arthur** [US/US]; Old County Road, Lincoln, Massachusetts 01773 (US). **LOBB, Roy** [US/US]; 569 Canton Street, Westwood, Massachusetts 02090 (US). **GHOSH, Shomir** [US/US]; 132 Sewall Avenue, Unit C, Brookline, Massachusetts 02446 (US). **ZHU, Zhendong** [US/US]; 8 Nipmuck Drive, Westborough, Massachusetts 01581 (US).

(74) Agent: **UNDERWOOD, Robert H.**; Mcdermott Will & Emery LLP, 28 State Street, Boston, Massachusetts 02109 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK,

[Continued on next page]

(54) Title: PROTEIN KINASE CONJUGATES AND INHIBITORS




FIG. 1

(57) Abstract: The invention relates to protein conjugates that contain a protein kinase containgn a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kinase is irreversibly inhibited. The invention also relates to compounds that irreversibly inhibit protein kinases.

WO 2011/034907 A2

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*